LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)
Launched by SEUNG-JUNG PARK · Dec 9, 2011
Trial Information
Current as of June 30, 2025
Terminated
Keywords
ClinConnect Summary
Following angiography, patients with significant diameter stenosis \> 50% and lesion length (\> 50mm) requiring at least 2 multiple long-stent placement by visual estimation and eligible for LONG-DES VI trial inclusion and exclusion criteria will be randomized 1:1 to zotarolimus-eluting stent (Resolute Integrity or Resolute Onyx stent) or everolimus-eluting stent (Xience Prime or Xience Xpedition or Xience Alpine stent) by the stratified randomization method.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age more than 20 years
- • Significant native coronary artery stenosis (\> 50% by visual estimate) with lesion length of more than 50mm, which requires at least 2 multiple long stent placement without intervening normal segment
- • Patients with silent ischemia, stable or unstable angina pectoris, and Non-ST-elevation myocardial infarction (NSTEMI)
- • The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site
- Exclusion Criteria:
- • Any contraindication to any of the following medications: aspirin, heparin, clopidogrel, stainless steel, contrast agents, zotarolimus, or everolimus
- • An elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs during the first 6 months post enrollment
- • Acute ST-segment-elevation MI or cardiogenic shock
- • Terminal illness with life expectancy \< 1 year
- • Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period
- • In-stent restenosis at target vessel (either bare metal stent or drug-eluting stent segment) However, non-target vessel In-stent restenosis is permitted
- • Patients with EF \< 30%
- • Serum creatinine level \>=2.0mg/dL or dependence on dialysis
- • Patients with left main stem stenosis (\> 50% visual estimate)
About Seung Jung Park
Seung-Jung Park is a distinguished clinical trial sponsor recognized for his commitment to advancing medical research and innovation. With a focus on cardiology and interventional procedures, he leads initiatives that aim to improve patient outcomes through rigorous clinical trials. His expertise in trial design and execution ensures adherence to the highest ethical standards and regulatory requirements. By fostering collaboration among multidisciplinary teams, Seung-Jung Park drives the development of cutting-edge therapies, contributing significantly to the scientific community and enhancing the landscape of modern medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Daegu, , Korea, Republic Of
Daegu, , Korea, Republic Of
Gwangju, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Chuncheon, , Korea, Republic Of
Seoul, , Korea, Republic Of
Suncheon, , Korea, Republic Of
Yangsan, , Korea, Republic Of
Ilsan, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Patients applied
Trial Officials
Seung-Jung Park, MD, PhD
Principal Investigator
Asan Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials